Sterility Testing Market Valuation Set to Worth Over US 2,945.74 Million By 2032 Membrane Filtration Test to Remain the Most Prominent and Highly Preferred Says Astute Analytica
| ALT Stock | USD 8.25 0.07 0.86% |
Slightly above 51% of Altimmune's private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Altimmune suggests that some traders are interested. Altimmune's investing sentiment can be driven by a variety of factors including economic data, Altimmune's earnings reports, geopolitical events, and overall market trends.
Altimmune |
ysd2YxJSEQOUID, n4BQe1q2Zey8MQDuJaa1vNHk6M28GEVOZ a8LxDaD8NZVqHc FOf
Read at finance.yahoo.com
 |
Altimmune Fundamental Analysis
We analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Altimmune is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Altimmune Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Altimmune stock to make a market-neutral strategy. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics with similar companies.
Peers
Altimmune Related Equities
| CGTX | Cognition Therapeutics | 8.62 | ||||
| INZY | Inozyme Pharma | 6.41 | ||||
| ATHA | Athira Pharma | 5.45 | ||||
| MDGL | Madrigal Pharmaceuticals | 5.12 | ||||
| AKRO | Akero Therapeutics | 3.31 | ||||
| CABA | Cabaletta Bio | 3.03 | ||||
| ARDX | Ardelyx | 2.77 | ||||
| DAWN | Day One | 2.65 | ||||
| SAVA | Cassava Sciences | 2.62 | ||||
| AVXL | Anavex Life | 1.89 | ||||
| VKTX | Viking Therapeutics | 1.83 | ||||
| ACAD | ACADIA Pharmaceuticals | 0.84 | ||||
| INMB | INmune Bio | 0.45 | ||||
| FBIO | Fortress Biotech | 1.15 | ||||
| ZURA | Zura Bio | 2.56 | ||||
| TERN | Terns Pharmaceuticals | 3.14 | ||||
| XFOR | X4 Pharmaceuticals | 4.69 | ||||
| HOOK | Hookipa Pharma | 5.61 | ||||
| VSTM | Verastem | 5.63 | ||||
| HEPA | Hepion Pharmaceuticals | 7.55 | ||||
| BIVI | Biovie | 8.65 | ||||
| RVPH | Reviva Pharmaceuticals | 10.67 |
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.